Alzheimer's disease drug development pipeline: 2024
Most Cited Paper
in Alzheimer's disease research and treatments
18 Months Post-Publication
Class of 2026
“Alzheimer's disease drug development pipeline: 2024”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Alzheimer's disease drug development · Common Alzheimer's Disease Research Ontology · disease-modifying biological agents · disease-modifying small molecule drugs · cognitive enhancing agents · neuropsychiatric symptoms treatment · Anti-amyloid therapy · neurotransmitter receptor-targeting therapies · synaptic plasticity-targeting therapies · inflammation-targeting therapies · new chemical entities · repurposed agents · Phase 1 clinical trials · Phase 2 clinical trials · Phase 3 clinical trial · ClinicalTrials.gov · drug repurposing · AD pipeline contraction 2023-2024 · FDA drug development timeline
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Alzheimer's disease research and treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/alzheimer-s-disease-research-and-treatments/2026. Accessed 2026-07-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459